Li-Chuan Chan

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

30h-index7.7kcitations104works0.52yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(43), Phagocytosis and Immune Regulation(43), Cancer Research and Treatments(29), Cancer Immunotherapy and Biomarkers(25), Immunotherapy and Immune Responses(16)

Publications104 total

RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer

3 cited

Signal Transduction and Targeted Therapy·2025· 3 citedOpen Access

Pivotal roles for cancer cell–intrinsic mPGES-1 and autocrine EP4 signaling in suppressing antitumor immunity

6 cited

JCI Insight·2024· 6 citedOpen Access

Supplementary Table 4 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Data from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 4 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

FIGURE 1 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

FIGURE 2 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Table 2 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 8 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 9 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 3 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 7 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 6 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 6 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 5 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 1 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Table 2 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Table 5 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 3 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

Supplementary Figure 2 from Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response

2024Open Access

page 1 of 6Next →

Frequent Co-authors

Mien‐Chie Hung(41), Weiya Xia(21), Jennifer L. Hsu(20), Jung-Mao Hsu(20), Heng‐Huan Lee(18), Yongkun Wei(16), Gabriel N. Hortobágyi(15), Jong‐Ho Cha(14), Jennifer L. Hsu(12), Chia‐Wei Li(11), Hirohito Yamaguchi(11), Jun Yao(11), Dihua Yu(11), Chia-Wei Li(11), Lei Nie(9), Ying‐Nai Wang(9), Linlin Sun(8), Shao‐Chun Wang(8), Yu‐Yi Chu(8), Seung-Oe Lim(7)